Approval Is Not Access. Access Is Not Adoption.

578 days from approval to the patient. Fewer than half of approved medicines actually available across the EU. And even where a medicine is listed, listed is not prescribed.

A drug can clear every visible gate and still never reach the patient it was built for.

The European Medicines Agency can say yes. NICE can say yes, with conditions. A national payer can say yes — but only after the patient has failed something cheaper first. The hospital pharmacy committee can say not yet. The treating physician can say maybe. And the patient, the one the molecule was designed for, can wait, switch, deteriorate, or never be diagnosed at all.

Every one of those answers is compatible with every other. A medicine can be approved, reimbursed, listed on a national formulary, and still not reach the people it exists to treat.

The approval is real. The reimbursement is real. The patient is missing anyway.

This is not a story about regulation failing. Regulation is working largely as designed: it confirms that a molecule is safe, efficacious, and manufacturable to standard, and then it stops. Whether the medicine reaches anyone is, by design, someone else’s question.

The trouble is that the industry often behaves as though approval and arrival were the same event, separated only by paperwork. They are not the same event. They are not even the same kind of event.

Approval is a regulatory decision. Access is a financial one. Adoption is a behavioural one.

The pharmaceutical industry is built to win the first, negotiates its way through the second, and quietly assumes the third.

The assumption is where the patients go missing.

The name of this publication is not a slogan. It is a diagnosis. Almost everything that decides whether a medicine becomes a therapy rather than a press release happens beyond approval — and that is the part of the system the industry is least organised to control.

Approval is binary and visible. A regulator says yes or no, on a published timeline, against a defined standard. The entire architecture of drug development — the trials, the statistical plans, the regulatory function, the evidence machine that produces the dossier — is optimised to clear this gate.

And the industry is genuinely good at it.

The problem is that the question the FDA and the EMA answer is not the question any payer is ultimately trying to resolve. Regulators ask whether a product is safe, efficacious, and approvable. Payers ask something else entirely: whether this product is worth more than the thing the system already funds, in the population it actually treats, at a price it is willing to pay.

Those are different questions.

Approval answers only the first.

So the molecule becomes a product. That is the whole of what approval does.

Approval is permission to sell. It is not permission to be paid.

A company that mistakes the regulator’s yes for the system’s yes has confused the starting line for the finish. The starting line is well lit, well rehearsed, and well funded. What comes after is slower, messier, more fragmented, and far less visible.

The second gate is access: reimbursement, national pricing, funding, and listing. It is slower, less visible, and decided by people who were never in the regulatory room.

The clearest measure of the distance between approval and access is the EFPIA W.A.I.T. Indicator, which tracks the time between EU marketing authorisation and the moment a medicine actually becomes available to patients. The European average is 578 days. In the fastest markets, patients may wait only a few months. In the slowest, they can wait more than two years.

That is not a rounding difference between systems. It is the same medicine, approved by the same agency, reaching patients at radically different speeds depending on where they live — if it reaches them at all.

And the gap is not only about time. It is also about availability. Of the innovative medicines approved by the EMA, the EU27 average for how many are actually available to patients remains below half. For some categories, including non-oncology orphan medicines, the picture is even weaker.

Approved and unavailable is not a theoretical category. It is a real access outcome.

Why does access stall? The reflex is to blame the payer for saying no. Often, that is exactly what happens. The payer may judge the evidence too uncertain, the comparator inappropriate, the benefit too incremental, the price too high, or the budget impact too difficult to absorb.

But increasingly, the access gate can also close from the company side.

A company may choose not to launch, or to launch late, because of where the price will travel once it is set. A list price in one country is not always a local fact. It can become an input into external reference pricing, international price comparisons, confidential discount expectations, and launch sequencing decisions across markets.

In that world, market access is not just a reimbursement process. It is a pricing architecture problem.

A company may accept that a country needs the medicine and still decide that launching there damages the global price corridor. The rational move for the P&L may be to delay the launch, deprioritise the market, or protect the international price anchor.

The empty market preserves the price.

The patient pays for the arithmetic.

This is why access delays cannot be understood only as administrative friction. Sometimes they are policy failure. Sometimes they are payer resistance. Sometimes they are company strategy. Often, they are all three at once.

The patient experiences them all the same way: the medicine exists, but not for them.

Suppose the molecule is approved. Suppose it is reimbursed and listed.

The medicine still has to be used.

This is the gate the industry resources last and measures worst, because it does not look like a gate at all. It looks like logistics. It is not logistics.

Formulary inclusion is not protocol inclusion. Protocol inclusion is not prescription. Prescription is not persistence. A medicine can be on every list and in no one’s hands.

Between listing and use sit the things no marketing authorisation touches: step-therapy rules that require a patient to fail a cheaper option first; treatment pathways written by clinicians who were never in the pricing negotiation; hospital budgets that absorb a listed drug slowly, or not at all; prescribing habits shaped by years of clinical routine; administrative frictions that make the old option easier than the new one; and beneath all of it, the diagnostic gap — the patients who are never identified, and so never treated, however available the medicine is.

The cleanest proof that access and adoption are different gates comes from biosimilars, because they remove many of the excuses.

The clinical uncertainty is substantially reduced. The economic incentive points in the right direction. The price is lower. The rationale is clear. And still, uptake varies widely between countries, products, and therapeutic areas.

Same regulatory standard. Same broad evidence logic. Same economic direction. Different adoption curves.

That variation is the point.

If products with established comparability and a clear cost-saving rationale can face uneven adoption, innovative therapies with more complex value stories, higher prices, diagnostic requirements, pathway disruption, and greater uncertainty will vary even more.

Listed is not prescribed.

Prescribed is not adopted.

Adoption is not a clinical problem. It is a behavioural and operational one. It is the point where evidence, incentives, clinical habits, budget flows, pathway design, patient identification, and implementation capacity either align or fail to align.

And it is the gate where launches fail most quietly.

Nothing visibly goes wrong. The drug was approved. The drug was reimbursed. The drug was listed. The launch deck was delivered. The price was agreed. The access milestone was celebrated.

The numbers in the launch plan simply never materialise.

By the time anyone asks why, the answer is spread across a thousand small frictions that no single team owned.

The gates do not fail for lack of evidence, expertise, or money. They fail because the industry is organised around the first one and treats the rest as downstream.

First, design for three gates from the first protocol, not one. The evidence that wins access and the evidence that drives adoption cannot be retrofitted after approval. The right comparator, the relevant endpoints, the generalisability of the study population, the patient pathway evidence, the treatment sequencing logic, the diagnostic requirements, the real-world implementation barriers, and the uptake mechanics all need to be understood early.

HTA cannot be reverse-engineered at the end of development. Neither can adoption.

By the time the dossier is being assembled, many of the decisions that determine the second and third gates have already been made.

Second, recognise that your organisation is built to clear gate one. Clinical development and regulatory own approval, and they are powerful, well funded, and structurally early. Access and adoption sit later in the timeline, lower in the budget, and split across functions that each own a fragment.

The payer, the clinician, and the patient do not experience value in fragments.

They experience the joins.

Third, budget the last mile as strategy, not support. The distance between listed and used is where the return on a launch is actually won or lost, and it is consistently one of the least-resourced parts of the plan.

The patients who never reach a reimbursed medicine do not appear in any P&L. They are not counted anywhere — which is precisely why the gap that produces them is so easy to ignore.

Fourth, measure success in patients treated, not approvals won or prices agreed. Approval is the milestone the industry is structurally best designed to pursue. It is also the milestone that says the least about whether the medicine did what it was built to do.

Approval is the day the molecule becomes a product. Access is the day it becomes available. Adoption is the day it becomes a medicine.

Only the third is measured in patients.

And it is the one the industry least directly controls.

The question is not only whether your molecule will be approved. For many well-funded programmes, that is the gate the industry is best equipped to clear. The harder question is whether your evidence, your price, and your launch sequence were built for the gate the regulator controls — or for the two gates the regulator never sees.

Because the agency can say yes, the payer can say yes, the formulary can say yes, and the patient can still be waiting.

Share

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients.